Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 May 8;6(5):e004513.
doi: 10.1161/JAHA.116.004513.

Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III

Kit N Simpson  1 , Annie N Simpson  2 , Patrick D Mauldin  3 , Yuko Y Palesch  4 , Sharon D Yeatts  4 , Dawn Kleindorfer  5 , Thomas A Tomsick  5 , Lydia D Foster  4 , Andrew M Demchuk  6 , Pooja Khatri  5 , Michael D Hill  6 , Edward C Jauch  7 , Tudor G Jovin  8 , Bernard Yan  9 , Rüdiger von Kummer  10 , Carlos A Molina  11 , Mayank Goyal  6 , Wouter J Schonewille  12   13 , Mikael Mazighi  14 , Stefan T Engelter  15   16 , Craig Anderson  17 , Judith Spilker  5 , Janice Carrozzella  5 , Karla J Ryckborst  6 , L Scott Janis  18 , Joseph P Broderick  5 ; Interventional Management of Stroke (IMS) III Investigators
Affiliations
Randomized Controlled Trial

Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III

Kit N Simpson et al. J Am Heart Assoc. .

Abstract

Background: Examination of linked data on patient outcomes and cost of care may help identify areas where stroke care can be improved. We report on the association between variations in stroke severity, patient outcomes, cost, and treatment patterns observed over the acute hospital stay and through the 12-month follow-up for subjects receiving endovascular therapy compared to intravenous tissue plasminogen activator alone in the IMS (Interventional Management of Stroke) III Trial.

Methods and results: Prospective data collected for a prespecified economic analysis of the trial were used. Data included hospital billing records for the initial stroke admission and subsequent detailed resource use after the acute hospitalization collected at 3, 6, 9, and 12 months. Cost of follow-up care varied 6-fold for patients in the lowest (0-1) and highest (20+) National Institutes of Health Stroke Scale category at 5 days, and by modified Rankin Scale at 3 months. The kind of resources used postdischarge also varied between treatment groups. Incremental short-term cost-effectiveness ratios varied greatly when treatments were compared for patient subgroups. Patient subgroups predefined by stroke severity had incremental cost-effectiveness ratios of $97 303/quality-adjusted life year (severe stroke) and $3 187 805/quality-adjusted life year (moderately severe stroke).

Conclusions: Detailed economic and resource utilization data from IMS III provide powerful evidence for the large effect that patient outcome has on the economic value of medical and endovascular reperfusion therapies. These data can be used to inform process improvements for stroke care and to estimate the cost-effectiveness of endovascular therapy in the US health system for stroke intervention trials.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Registration number: NCT00359424.

Keywords: cost; cost‐effectiveness; ischemic; stroke; stroke care; tissue‐type plasminogen activator.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Details of the populations included in the economic analyses. *US subjects; #non‐US subjects. Note: The index hospital admission is the initial admission for stroke. FU costs are calculated from resource use data collected at the 3‐, 6‐, 9‐, and 12‐month follow‐up visit or call. FU indicates follow‐up; QALY, quality‐adjusted life year.
Figure 2
Figure 2
Distribution of costs after initial acute stroke hospitalization by type of resources used over the 12 months by treatment group. EVT indicates subjects randomized to endovascular therapy; IV Only are subjects who are randomized to receive only intravenous tissue plasminogen activator; Q1 through Q4 indicate first through fourth quarter year in the study; Rahab, cost for rehabilitation care; Hospital, cost of hospital admissions; ER, cost of emergency visits; Office, cost of medical office visits; HomeHlt, cost of home health care; HomeAid, cost of care delivered by home health aids; NsgHome, cost of days in a skilled nursing facility.
Figure 3
Figure 3
Severe stroke only: distribution of costs after initial acute stroke hospitalization by type of resources used over the 12 months by treatment group. EVT indicates subjects randomized to endovascular therapy; IV Only are subjects who are randomized to receive only intravenous tissue plasminogen activator; Q1 through Q4 indicate first through fourth quarter year in the study; Rahab, cost for rehabilitation care; Hospital, cost of hospital admissions; ER, cost of emergency visits; Office, cost of medical office visits; HomeHlt, Cost of home health care; HomeAid, cost of care delivered by home health aids; NsgHome, cost of days in a skilled nursing facility.
Figure 4
Figure 4
Variations in differences in cost and QALYs for patients with severe stroke based on 1000 bootstrap replications. Note: The panel on the left shows the distribution of cost and QALYs from 1000 bootstrap estimates for patients with severe stroke. The right‐hand panel shows the cost‐effectiveness acceptability curve for the ICERs produced by 1000 bootstrap replications for subjects with severe stroke based on observed QALYs and observed or estimated costs for all subjects with severe stroke at baseline. ICERs indicates incremental cost‐effectiveness ratios; QALYs, quality‐adjusted life years.
Figure 5
Figure 5
Effect of uncertainty on ICERs presented in Table 4. Note: The panels show the distribution of cost and QALYs from 1000 bootstrap estimates for the respective patient groups. ICERs indicates incremental cost‐effectiveness ratios; MD, physician costs included; QALYs, quality‐adjusted life years.
See this image and copyright information in PMC

References

    1. Lindsay P, Furie KL, Davis SM, Donnan GA, Norrrving B. World Stroke Organization global stroke services guidelines and action plan. Int J Stroke. 2014;9:4–13. - PubMed
    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Heart disease and stroke statistics 2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322. - PubMed
    1. Thrift AG, Cadilhac DA, Thayabaranathan T, Howard G, Howard VJ, Rothwell PM, Donnan GA. Global stroke statistics. Int J Stroke. 2014;9:6–18. - PubMed
    1. Svendsen ML, Ehlers LH, Hundborg HH, Ingeman A, Johnsen SP. Process of early stroke care and hospital cost. Int J Stroke. 2014;9:777–782. - PubMed
    1. Dawson J, Lees JS, Chang TP, Walters MR, Ali M, Davis SM, Diener HC, Lees KR; GAIN and VISTA Investigators . Association between disability measures and healthcare cost after initial treatment for acute stroke. Stroke. 2007;38:1893–1898. - PubMed

Publication types

MeSH terms

Substances

Associated data